AstraZeneca's Baxdrostat achieves breakthrough blood pressure reductions in Phase III Bax24 trial

Patients on baxdrostat showed a significant reduction in systolic blood pressure (SBP) compared to placebo

Revvity launch new somatic cancer reference standards to to boost precision in oncology diagnostics

The new MimixTM GeniTM reference standards were developed from the extensively tested Genome-in-a-Bottle Consortium (GIAB) cell line

Teva’s AUSTEDO and AUSTEDO XR demonstrate real-world improvement in patients with tardive dyskinesia

The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life

Gilead’s Trodelvy falls short on progression-free survival in key breast cancer trial

While the trial fell short of demonstrating a statistically significant PFS benefit compared to chemotherapy, early data suggest a potential overall survival advantage

Zydus Lifesciences posts Q2 FY26 PAT at Rs. 1,258.6 Cr

Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives

Novo Nordisk India partners with Emcure to commercialise Poviztra in India

Poviztra is a second brand of Wegovy

MSD secures $700 million boost from Blackstone to advance broad-cancer ADC therapy Sac-TMT

Valneva’s next-gen Zika vaccine shows strong safety and immune response in phase I trial

VLA1601 is a purified and inactivated vaccine specifically designed to protect against the Zika virus

Zydus wellness reports 31% growth in net sales in Q2 FY26

During the quarter, Zydus Wellness completed the acquisition of Comfort Click Limited and its subsidiaries

J&J MedTech reports strong one-year results for shockwave peripheral IVL system in DISRUPT BTK II trial

The study demonstrated strong clinical outcomes, with 94.8 per cent of subjects remaining free from major target limb amputation at one year